GlaxoSmithKline

PDF document with encoded content, possibly a technical or academic paper.

Conference on global health and clinical trials addresses bioethics, regulations, patient recruitment, site selection, real-world data, data integration, outsourcing, vendor management, quality in trial conduct, risk-based monitoring, clinical auditing, financial planning, and innovative technologies. Focuses on networking, case studies, presentations, and round tables.

Switch the Market flag for targeted data from your country of choice. Right-click on the chart to open the Interactive Chart menu. Use up/down arrows to move through symbols.

Science 37 contributed almost half of U.S. enrollment for GSK's Phase 3 rare disease trial, leveraging its Direct-to-Participant Site solution to expand access and reduce participant burden. The decentralized approach facilitated real-time, at-home data collection, enhancing patient engagement and study continuity, with 82.3% completing Part A of the trial.

The Global Clinical Trials Connect 2025 conference will discuss futuristic advancements in clinical trials, focusing on innovative strategies, new technologies, and quality collaborations to address increased complexity. Topics include patient recruitment, site selection, real-world data, and risk-based monitoring, among others. The event targets senior-level professionals from pharmaceutical, bio-tech, and CRO companies, offering networking and case study opportunities.

The Global Clinical Trials Connect 2025 conference will discuss futuristic advancements in clinical trials, focusing on innovative strategies, new technologies, and quality collaborations to address increased complexity. Topics include patient recruitment, site selection, data integration, outsourcing, and risk-based monitoring. The event targets senior-level professionals from pharmaceutical, bio-tech, and CRO companies, offering networking and case study presentations.

Science 37 contributed 17-47% of U.S. enrollment for GSK's Phase 3 rare disease trial, achieving 82.3% completion for Part A. Their Direct-to-Participant Site solution enabled home-based participation, overcoming geographical barriers.